Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
12 avr. 2024 08h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
09 avr. 2024 07h30 HE
|
Knight Therapeutics
MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia,...
Knight présentera à la conférence des investisseurs en santé Bloom Burton & Co. 2024
09 avr. 2024 07h30 HE
|
Thérapeutique Knight inc.
MONTRÉAL, 09 avr. 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD), société pharmaceutique spécialisée panaméricaine (ex-ÉU) et chef de file, a annoncé aujourd'hui que Samira...
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
03 avr. 2024 07h30 HE
|
Mereo BioPharma Group plc
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Ardelyx, Inc. Reports Employment Inducement Grants
28 mars 2024 16h05 HE
|
Ardelyx, Inc.
WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity
28 mars 2024 11h03 HE
|
Knight Therapeutics
MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2024 Report on...
Thérapeutique Knight inc. se mérite une place à la cinquième édition du classement Women Lead Here du Globe and Mail sur la diversité des femmes cadres
28 mars 2024 11h03 HE
|
Thérapeutique Knight inc.
MONTRÉAL, 28 mars 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou « la Société ») a le plaisir d’annoncer sa nomination à la cinquième liste annuelle Women Lead...
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
27 mars 2024 16h01 HE
|
Mereo BioPharma Group plc
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively ...
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
25 mars 2024 08h00 HE
|
Ardelyx, Inc.
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
21 mars 2024 07h30 HE
|
Knight Therapeutics
MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported...